Related Experiment Videos
Summary
Hormones like estrogens can promote cancer growth, particularly breast and endometrial cancer, with increased risk linked to longer use after menopause. Progestin may reduce endometrial cancer risk, while prolactin
Area of Science:
- Endocrinology
- Oncology
- Epidemiology
Background:
- Hormones can function as cocarcinogens or promoters, facilitating cancer development.
- Growth-promoting hormones may increase carcinogenesis risk in human breast and endometrium.
- Estrogen use post-menopause is linked to higher breast and endometrial cancer incidence.
Purpose of the Study:
- To review the role of hormones, particularly estrogens and prolactin, in human carcinogenesis.
- To evaluate the impact of hormone replacement therapy on cancer risk.
- To discuss potential mitigation strategies for hormone-associated cancers.
Main Methods:
- Review of experimental and epidemiological evidence on hormone and cancer links.
- Analysis of studies on estrogen, progestin, and prolactin in relation to cancer incidence.
- Examination of specific hormone exposures like diethylstilbestrol and prolactin-releasing drugs.
Main Results:
- Estrogen use post-menopause increases breast and endometrial cancer risk, dose-dependently.
- Periodic progestin withdrawal may decrease endometrial cancer risk.
- Prolactin's role in human breast cancer is under investigation; studies on prolactin-releasing drugs show no increased risk.
Conclusions:
- Estrogens are implicated as promoters in human breast and endometrial carcinogenesis.
- Hormone therapy decisions require careful risk-benefit assessment regarding cancer.
- Further research is needed to clarify prolactin's role in human mammary carcinogenesis.